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Abstract 
Differences in NT-proBNP levels in the normal range bear prognostic impact for long term
mortality. The determinants of NT-proBNP in healthy subjects however are unknown. The
natriuretic peptide axis and the renin-angiotensin-aldosterone system (RAAS) play opposite
roles in the regulation of volume homeostasis. We therefore tested the hypothesis that individual
differences in NT-proBNP level are related to differences in RAAS-activity. 
Thirty-five healthy men (age: 24 (21-27) years) completed a double blind placebo controlled
protocol of two two-week periods. Both periods were one week on a low (low sodium, LS, 50
mmol/24h) and one week on a high sodium diet (HS, 200 mmol/24h), during placebo and
during RAAS blockade (ACE-inhibition), respectively. RAAS-parameters, renal hemodynamics,
extracellular volume (ECV) and the renal response to angiotensin II were measured at the end
of each week and related to NT-proBNP levels, continuously, and according to a break-up by
NT-proBNP below or above group median. 
HS induced a decrease in plasma renin activity and a rise in NT-proBNP, effective renal
plasma flow (ERPF) and ECV. Except for NT-proBNP, all parameters were similar between
subjects with NT-proBNP above versus below the group median during LS. Subjects with an
NT-proBNP above group median however had a blunted ERPF response to sodium (5 ± 45
vs. 73 ± 50 mL/min, p<0.001) and consequently, a lower ERPF during HS (542 ± 85 vs. 618 ±
76 mL/min, p<0.01), along with a blunted PRA suppression. The renal response to ang II/kg/min
was blunted in subjects with higher NT-proBNP (-164 ± 44 vs. -223 ± 47 mL/min decrease in
ERPF, p<0.001). In subjects with a higher NT-proBNP ACEi induced a rise in ERPF during HS
(from 542 ± 85 to 579 ± 108 mL/min, p<0.05) that was absent in the lower NT-proBNP group.
ECV was not different between subjects with higher or lower NT-proBNP on either sodium
intake. 
A higher NT-proBNP level in the normal range is associated with blunted responses of ERPF
and PRA to HS, and to exogenous angII, and an exaggerated response to ACEi during HS.
Together, these data indicate that higher NT-proBNP in the normal range reflects less effective
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Introduction
Elevated NT-proBNP levels predict a worse cardiovascular (CV) outcome in populations
with CV disease (1). Remarkably, higher NT-proBNP levels within the normal range bear
prognostic impact as well, as shown in general population cohorts (2). Whereas sodium status
(3-5) and genetic factors (6) are known to influence NT-proBNP levels, the determinants of
individual differences in NT-proBNP within the normal range, have not been well-established. 
The natriuretic peptide axis and the renin-angiotensin-aldosterone system (RAAS) play
opposite roles in volume homeostasis. During volume depletion the RAAS is activated, leading
to systemic and renal vasoconstriction and renal sodium retention, thus ensuring stability of
blood pressure and glomerular filtration and restoration of extracellular volume. Concomitantly
low natriuretic peptide levels facilitate the anti-natriuretic actions of the RAAS. During volume
expansion on the other hand, RAAS activity is suppressed and natriuretic peptide levels
increase, to ensure adequate renal excretion of larger amounts of sodium.
Considering the opposite roles of the natriuretic peptide axis and the RAAS in volume
homeostasis, we hypothesized that individual differences in NT-proBNP levels in the normal
range might be related to individual differences in regulation of RAAS-activity. To test this
hypothesis, in the current study we studied healthy men during low and high sodium intake,
and studied the association of NT-proBNP levels with the circulating plasma renin-activity as
well as with parameters of intrarenal RAAS-activity, i.e the responses of effective renal plasma




Thirty-five healthy male volunteers were recruited for the study. They were all normotensive,
having a sitting systolic blood pressure < 140 mmHg and diastolic blood pressure < 80 mmHg.
All subjects underwent routine physical examination which revealed no significant
abnormalities. Written informed consent was obtained after thorough explanation of the study.
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Study protocol
The protocol consisted of two different two week periods separated by a wash-out period
of minimum 6 weeks. Each period, subjects adhered to a low sodium diet for 7 days (50 mmol
Na
+
/24h) followed by a week on a high sodium intake (200 mmol Na
+
/24h). Subjects used
enalapril (20 mg/ day) or placebo for two weeks both, in randomized order. Diets were based
on personal food habits and differences in sodium intake were achieved by replacing sodium-
rich products with low-sodium products in the same food category in order to remain isocaloric
with a similar balance between protein, carbohydrate and fat. Potassium intake was
standardized at 80 mmol/24h. On day 4 and day 6 of each week, subjects collected 24h-urine
samples to assess dietary compliance.
At day 7 of each study period, the subjects reported at the research unit at 8.00h am, after
having abstained from food and alcohol overnight. Height and body weight was measured at
the start of this day and BMI was calculated as the ratio of body weight (kg) and the square
of height (m). During the study day, subjects remained in a semi-supine position except during
voiding.
Sodium intake during the day was adjusted according to the actual diet in the concerning
period. To ensure sufficient urine output, 250 mL of 5% glucose solution was infused and
subjects were provided with 250 mL of oral fluids every hour. After a run-in period, glomerular
filtration rate (GFR) and effective renal plasma flow (ERPF) were measured as the clearances
of continuously infused 
125
I - Iothalamate and 
131
I – Hippuran, respectively. In this setup, GFR
is measured as the urinary clearance of 
125
I- Iothalamate, and corrected for voiding errors by
the ratio of plasma to urinary clearance of 
131
I- Hippuran, as described in more detail previously
(7;8). The coefficient of variation of this method is 2.5% for GFR and 5% for ERPF. FF was
calculated as the ratio of GFR and ERPF and expressed as percentage (%). Extracellular
volume (ECV) was determined as the distribution volume of 
125
I- Iothalamate during steady
state, as described in more detail previously (9). Briefly, ECV was calculated as [sum (I*V +
(B*V) – sum (U*V)]/P
Iothalamate
during steady state. B*V represents the total amount of bolus
infusion of the tracer. Sum (U*V) is the total amount of 
125
I-Iothalamate excreted in the urine.
Sum (I*V) is the total infused amount of 
125
I-Iothalamate. Blood pressure was assessed with
an automatic device (Dinamap) at 15 min intervals. Mean arterial pressure was calculated as
diastolic pressure plus one-third of the pulse pressure. 
Angiotensin II infusion
Baseline values for blood pressure, GFR and ERPF were obtained from 10 to 12 am. Between
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was administered at a constant rate of 0.3, 1 and 3 ng/kg/min, each for a 1-h period, in a
consecutive manner. During ang II infusion, blood pressure was measured at 5 minute intervals. 
Chemical analysis of urine and blood samples
Urinary concentration of sodium, potassium and urea was measured by standard auto-
analyser technique (MEGA, Merck, Darmstadt, Germany). Plasma renin activity (PRA) was
determined in terms of angiotensin I generation using a radioimmunoassay (10). Aldosterone
was measured with a commercially available radioimmunoassay kit (Diagnostic Products
Corporation, Los Angeles, California, USA). Plasma glucose was determined by glucose-
oxidase method (YSI 2300 Stat plus, Yellow Springs, OH). NT-proBNP measurements were
performed in serum at the core laboratory of our center, on an Elecsys 2010 analyser, a
commercially available electrochemiluminescent sandwich immunoassay (Elecsys proBNP,
Roche Diagnostics, Mannheim, Germany). The intra- and interassay coefficients of variation
were 1.2-1.5% and 4.4-5.0%, respectively, with an analytical range of 5-35.000 pg/mL.
Data analysis
Data were analyzed using SPSS 16.0 (SPSS Inc. Chicago, IL, USA). Data with a normal
distribution are expressed as mean ± standard deviation (SD). Non-parametric parameters
are given as median (interquartile range). The effect of ACEi and sodium diet was assessed
by paired sample T-test for parametric data and Wilcoxons signed rank test for non-parametric
data. The effect of NT-proBNP on the renal hemodynamic response to ACEi was analyzed
according to NT-proBNP split-up by median and by continuous analysis. Differences in renal
hemodynamic response to ACEi between NT-proBNP > and < median were analyzed by
Student’s T-test. Continuous analysis was performed with Spearmens rank correlation analysis.
A two-sided p-value <0.05 was considered to be significant. 
Results
Median (interquartile range) age was 24 (21-27) years. Mean BMI was 23.0 ± 2.3 kg/m
2
.
Table 1 displays characteristics of the subjects during the four periods. It shows first that the
differences in diets resulted in the expected differences in 24-h sodium excretion (UNaV),
reflecting a good compliance to the diet. The 24-h excretion of potassium (UKV) was around
the target excretion of 80 mmol/24h with a slight but significantly lower excretion during the
HS-ACEi period. The high sodium diet resulted in a significant increase in body weight and
7
126
NT-proBNP is a marker of increased intrarenal RAAS-activity





LS HS LS HS
UNaV (mmol/ 24h) 37 ± 23 219 ± 56 <0.001 49 ± 22 # 222 ± 72 <0.001
UKV (mmol/24h) 83 ± 27 78 ± 20 ns 88 ± 26 74 ± 22 0.001
Weight (kg) 79.1 ± 9.4 80.4 ± 9.5 <0.001 78.4 ± 9.0 80.3 ± 9.4 <0.001
ECV (L) 19.1 ± 2.9 20.4 ±3.0 <0.01 18.4 ± 2.6 20.2 ± 3.2 <0.001
NT-proBNP (ng/L) 26 (15-34) 36 (28-50) <0.001 11 (7-15) ** 28 (17-47) <0.001
MAP (kg) 85 ± 7 88 ± 8 <0.05 82 ± 8 * 82 ± 8 ** ns
GFR (mL/min) 124 ± 17 134 ± 20 0.001 128 ± 18 # 135 ± 19 0.001
ERPF (mL/min) 541 ± 82 579 ± 88 <0.001 595 ± 90 ** 605 ± 93 * ns
FF (%) 23.2 ± 2.6 23.2 ± 2.3 ns 21.7 ± 2.0 ** 22.5 ± 1.9 # <0.05
Tabel 1: body weight, MAP, renal hemodynamics, UNaV and UKV during the four treatment periods
Abbreviations: LS: low sodium diet, HS: high sodium diet, ACEi: ACEi inhibition, MAP: mean arterial pressure, ERPF:
effective renal plasma flow, GFR: glomerular filtration rate, FF: filtration fraction, UNaV: 24h urinary sodium excretion,
UKV: 24h urinary potassium excretion, ECV: extra cellular volume,  # p<0.05 vs placebo- same diet, * p<0.01 vs
placebo same diet, ** p<0.001 vs placebo same diet
NT-proBNP during LS
p
< median > median
NT-proBNP (ng/L) 15 (11-23) 34 (29-47) by default
ERPF LS (mL/min) 544 ± 68 537 ± 94 ns
ERPF HS (mL/min) 618 ± 76 542 ± 85 <0.01
ERPF LS-ACEi (mL/min) 618 ± 75 573 ± 99 ns
ERPF HS-ACEi (mL/min) 632 ± 66 579 ± 108 ns
PRA LS (ng ang-I/mL/hr) 5.9 (4.3-8.5) 6.4 (4.5-8.1) ns
PRA HS (ng ang-I/mL/hr) 1.8 (1.2-3.2) 3.1 (2.0-4.1) <0.05
Aldosterone LS (ng/L) 130 (85-192) 132 (79-167) ns
Aldosterone HS (ng/L) 38 (24-50) 45 (29-80) ns
Table 2: ERPF, PRA and aldosterone according to a split-up by median NT-proBNP during LS 
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ECV both during placebo and during ACEi, consistent with a positive volume balance. Along
with an increase in ECV, HS induced a significantly higher NT-proBNP during placebo and
during ACEi. Furthermore, ACEi significantly reduced NT-proBNP during LS, but not during
HS. During placebo but not during ACEi, HS significantly increased MAP. As expected, MAP
was significantly decreased by ACEi. During placebo ERPF and GFR were significantly
increased by HS. There was no effect of sodium intake on FF. ACEi significantly increased
ERPF during both diets. GFR was increased by ACEi only during LS. FF was significantly
decreased by ACEi during both sodium intakes with the lowest value during ACEi-LS (p<0.05
vs ACEi-HS). 
NT-proBNP, ERPF and circulating RAAS parameters
In table 2 ERPF during al four conditions and serum aldosterone and PRA during LS and
HS are displayed according to NT-proBNP during LS split-up by median. The table shows
that during LS ERPF was similar in both NT-proBNP groups. On HS ERPF was significantly
lower in the high NT-proBNP group. ACEi blunted the difference in ERPF between the two
groups. Subjects in the high NT-proBNP group had a blunted suppression of PRA during HS.
There were no differences in aldosterone between the two groups on either sodium intake.
Renal vasodilator response to HS and ACEi
Figure 1a shows the relative change in ERPF (∆ERPF) from its value during LS, again split-
up according to median NT-proBNP during LS. It shows that the renal vasodilator response
to HS was almost completely blunted in the high NT-proBNP group (solid line), whereas ACEi,
in combination with either sodium intake, induced an increase in ERPF as compared to LS. In
the low NT-proBNP-group (dotted line), ACEi had no additional vasodilator effect to HS. 
On continuous analysis, NT-proBNP was significantly correlated to the change in ERPF as
induced by HS (R=-0.57, p<0.001).
In figure 1b the relative change of ERPF (∆ERPF) as induced by ACEi during HS is displayed.
Again data are split–up according to median NT-proBNP during LS. The figure shows that in
the high NT-proBNP group ACEi induced a significant increase in ERPF, whereas this increase
was absent in the low NT-proBNP group.
ERPF response to angiotensin II
The decrease in ERPF (∆ERPF) as induced by infusion of 3 ng ang II/kg/min during the four
treatment periods are displayed in figure 1c. Again data are split-up according to median NT-
7
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Figure 1 (left page): Responses of ERPF to HS, ACEi and angiotensin II, data split-up according to
median NT-proBNP during LS (dotted line; NT-proBNP<median, solid line; NT-proBNP>median)
a: change in ERPF from value on LS as induced by a HS, LS-ACEi and HS-ACEi 
b: change in ERPF as induced by ACEi during HS 
c; decrease in ERPF as induced by exogenous angiotensin II during the four study periods 
abbreviations: ERPF: effective renal plasma flow, HS: high sodium diet, LS: low sodium diet, ACEi: ACE-
inhibition. * p<0.05 between NT-proBNP above and below median. # p<0.05 vs HS 
proBNP during LS. On LS no differences in ang II induced decrease in ERPF occurred between
the two groups. In contrast, on HS the decrease in ERPF as induced by ang II was significantly
blunted in the high NT-proBNP group. During ACEi (both sodium diets), there were no
differences in ∆ERPF between the groups. During HS, NT-proBNP was significantly correlated
to the response of ERPF to ang II infusion at a rate of 3 ng/kg/min (R=-0.52, p<0.01).
Also at HS, at the rate of 0.3 ng/kg/min and 1 ng/kg/min infusion of ang II the decrease in
ERPF was significantly blunted in the higher NT-proBNP group, being -75 ± 53 and -34 ± 40
mL/min (p<0.05) at 0.3 ng/kg/min and -153 ± 36 and -99 ± 49 mL/min (p=0.001), respectively.
During LS, LS-ACEi and HS-ACEi the decrease in ERPF as induced by 0.3 ng/kg/min and 1
ng/kg/min ang II was similar in the two groups (data not shown). 
Discussion
Our study examined the relationship between NT-proBNP and the circulating parameters
of the RAAS as well as parameters of intrarenal RAAS activity. High NT-proBNP was associated
with a blunted suppression of PRA and a blunted renal vasodilator response to HS. Moreover,
during HS, the response to ACEi was significantly enhanced in the high NT-proBNP group. In
addition, during HS, when the greatest impact of NT-proBNP on ERPF was observed, the
response of ERPF to exogenous ang II was significantly higher in the lower NT-proBNP group.
The present study demonstrates that activity of intrarenal RAAS is related to NT-proBNP. It
suggests that next to sodium intake and genetic factors, activity of the (intrarenal) RAAS is an
important determinant of NT-proBNP in healthy subjects. 
The role of the RAAS in determining renal perfusion has been the focus of different studies
in the past mainly performed by Hollenberg and colleagues. In particular, an increased activity
of the intrarenal RAAS is a consistently characterized trait which may be associated with (the
development of) salt sensitive hypertension and kidney damage (11). Increased intrarenal
RAAS activity is characterized by a blunted renal vasodilator response to a high sodium intake
7
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(12;13), a blunted response to exogenous angiotensin II (12;13) and a more pronounced renal
hemodynamic response to RAAS blockade (14). 
The cardiac natriuretic system is the physiologic reciprocal acting counterpart of the RAAS.
The interaction of both systems in determining renal perfusion has never been investigated.
We assessed the renal hemodynamic response according to NT-proBNP during LS, split–up
by median. During LS, no difference in renal perfusion was apparent between the two groups.
Strikingly, the renal vasodilator response to HS was almost completely blunted in the higher
NT-proBNP group leading to a significantly lower ERPF in the higher NT-proBNP group during
HS. During ACEi (LS and HS), the difference in ERPF between the two groups was not
significant, indicating that the inability of the renal vasculature to respond to a higher sodium
intake in the higher NT-proBNP can at least partly be restored by ACEi. We assessed the renal
vasoconstrictor response to exogenous angiotensin II as an indirect estimate of intrarenal
RAAS–activity. On group level the renal vasoconstrictor response to angiotensin II was
enhanced by HS. Noticeable, in the higher NT-proBNP group, the vasoconstrictor response
to angiotensin II was significantly smaller than the response in the lower NT-proBNP group.
Moreover, this difference could be fully restored by ACEi. These findings clearly indicate that
the subjects in the higher NT-proBNP group, having a blunted vasodilator response to HS
and a blunted vasoconstrictor response to angiotensin II, have an increased intrarenal RAAS
activity (12;13). Another characteristic of increased intrarenal RAAS activity is the pronounced
renal vasodilator response to RAAS-blockade during HS (12;14). We could only detect a
significant increase in ERPF in response to ACEi in the higher NT-proBNP group whereas the
response in the low NT-proBNP was non significant (p=0.26). The increase in ERPF in response
to ACEi during HS was 14 ± 51 mL/min and 36 ± 60 for the lower and higher NT-proBNP group.
Unfortunately, this difference did not reach statistical significance (p=0.25), which might most
probably be due to the small number of subjects in the study. 
The phenotype of increased intrarenal RAAS activity has been most extensively studied in
patients with essential hypertension. In these subjects, increased intrarenal RAAS activity has
been coupled to salt sensitivity of blood pressure (15) . The inability of these subjects to
increase their renal blood flow in response to HS probably hampers a sufficient sodium
excretion. Consequently, extra cellular volume piles up until sodium balance is restored, albeit
with increased blood pressure. In line with this theory, it seems quite plausible that an inability
to excrete sufficient amounts of sodium is compensated by an increase in activity of the cardiac
natriuretic system. 
Increased intrarenal RAAS activity has also been observed in obesity (16), which is
associated with sodium sensitive hypertension (17) and type II diabetes (16;18). Even in healthy
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intrarenal RAAS has been observed (19). In this study we only included subjects who were
healthy, young, normotensive and non-obese. Therefore, there were no differences in age and
BMI between the two groups. 
This study has a number of limitations. Currently, no longitudinal data are available regarding
the meaning of an increased intrarenal RAAS activity. As our subjects were healthy and had
no signs of an underlying pathology, long term prospective data are needed to assess whether
an increased intrarenal RAAS activity at a young age predicts the development of hypertension
or kidney damage. We studied our subjects in different diet periods lasting a week. Although
sodium balance is restored within this period, we have no information about the long term
effects of the diet. We included only male subjects in this study, as the menstrual cycle has
considerable impact on renal hemodynamics (20). Therefore straightforward extrapolation of
our data to female subjects is not warranted. 
In conclusion, our study demonstrates that a higher NT-proBNP in healthy subjects is
associated with a blunted renal vasodilator response to HS. Moreover, these subjects had a
blunted renal response to exogenous Ang II which was restored by ACEi. These data suggest
that a higher NT-proBNP indicates an inappropriate activity of the intrarenal RAAS. Whether
this phenomenon is involved in the increased cardiovascular risk of higher NT-proBNP should
be subject of future prospective studies. 
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